Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP, Pınar; Eralp, YEŞİM; AYDOĞMUŞ ŞEN, Fatma; Karaca, H.; ÖZKAN, METİN; ÇETİN, BEKİR; Benekli, M.; Kucukoner, M.; Isikdogan, A.; Un, O.; BAŞARAN, Gül; Onur, H.

doi:10.1016/j.breast.2013.07.048

Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

Copy For Citation

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., ...More

BREAST, vol.22, no.5, pp.628-633, 2013 (SCI-Expanded)

Publication Type: Article / Article
Volume: 22 Issue: 5
Publication Date: 2013
Doi Number: 10.1016/j.breast.2013.07.048
Journal Name: BREAST
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.628-633
Keywords: HER2 positive, Lapatinib, Metastatic breast cancer, Vinorelbine, PLUS VINORELBINE, 1ST-LINE THERAPY, TRASTUZUMAB, SURVIVAL, GROWTH
Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Background: The aim of this explorative phase II study was to evaluate the activity and safety of lapatinib in combination with intravenous vinorelbine in women with HER2 positive metastatic or recurrent breast cancer.